Microba Secures $5M to Achieve Cashflow Breakeven and Growth
Key points
- $5.0 million placement secured at $0.05 per share
- Streamlined operations and AI enhancements to drive cashflow break-even
- 11 consecutive quarters of core testing sales growth
- New category-defining testing product to launch in Q3 CY26
- Eligible shareholders can apply for up to $30,000 of new shares
Full summary
Microba Life Sciences Ltd has successfully secured $5 million through a placement at $0.05 per share, supported by existing and new institutional investors. Major shareholder Sonic Healthcare Limited invested $1.5 million. The funds will support Microba's path to cashflow break-even by streamlining operations and AI enhancements. Core testing sales have grown by 106% in the last year, driven by enterprise-style healthcare contracts. A new category-defining testing product is set to launch in Q3 CY26, catalyzing further diagnostics growth. Eligible shareholders can apply for up to $30,000 of new shares under a Share Purchase Plan at the same offer price. An investor webinar will be held on 16 June 2026.
Guidance
Microba aims for whole company cashflow break-even in CY2027.
Outlook
Microba expects to achieve cashflow break-even by Q3 CY26 and continue core testing growth with the new product launch.
Summary generated by a large language model. Please interpret with care.